The Filing Desk

Rigel Pharmaceuticals vs Xeris Biopharma

Rigel Pharmaceuticals RIGL · Xeris Biopharma XERS · Pharmaceuticals

Rigel Pharmaceuticals reported revenue of $294 million in fiscal 2025, about the same as Xeris Biopharma's $292 million in fiscal 2025. Rigel Pharmaceuticals' revenue grew 64.2% in its latest year, and Xeris Biopharma's grew 43.7%. Rigel Pharmaceuticals had an operating margin of 42.6%, against 8.5% at Xeris Biopharma.

Side by side

Rigel PharmaceuticalsXeris Biopharma
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$294M$292M
Revenue growth64.2%43.7%
Revenue growth a year, last 5 years22.1%70.3%
Gross margin93.3%—
Operating margin42.6%8.5%
Net margin124.7%0.2%
Free cash flow——
Free cash flow margin——
Return on capital91.3%19.6%
Net debt to EBITDA−0.8x4.2x
Dividends and buybacks$0M$0M
Change in diluted share count6.5%17.7%
Last close$44.46$16.66
P/E at the last close2.8×—
Insider trades, last 12 months—sold $4.7 million
Piotroski F-score7 of 97 of 8
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
Rigel PharmaceuticalsXeris Biopharma
Operating margin
Percent of revenue
Rigel PharmaceuticalsXeris Biopharma
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Rigel PharmaceuticalsXeris Biopharma

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Rigel Pharmaceuticals and Xeris Biopharma pages.